There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was
first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The …

Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism
in EGFR-mutant adenocarcinomas that have progressed on erlotinib. Third-generation …

Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied …

Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung
cancer whose tumors had developed resistance to the epidermal growth factor receptor …

Protein kinases have grown over the past few years as a crucial target for different cancer
types. With the multifactorial nature of cancer, and the fast development of drug resistance …

The success of tyrosine kinase inhibitors (TKIs) in select patients with non–small-cell lung
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …

Lung cancer has a high prevalence, with a growing number of new cases and mortality
every year. Furthermore, the survival rate of patients with non-small-cell lung carcinoma …

Uncommon epidermal growth factor receptor (EGFR) mutations collectively account for 10%
of EGFR mutations, harboring heterogeneous molecular alterations within exons 18–21 with …

Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …